{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Wang M"],"pubmed_abstract":["<h4>Study objectives</h4>Cannabidiol (CBD) is increasingly used as a health supplement, though few clinical studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in individuals with insomnia.<h4>Methods</h4>In this double-blind, placebo-controlled, randomized clinical trial, 125 individuals with insomnia received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene) for ≥ 4 days/wk over 4 weeks using a crossover design. The study medication was devoid of Δ<sup>9</sup>-tetrahydrocannabinol. The primary outcome measure was the percentage of time participants spent in the combination of sl"],"journal":["Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine"],"pagination":["69-80"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11701282"],"repository":["biostudies-literature"],"pubmed_title":["Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study."],"pmcid":["PMC11701282"],"pubmed_authors":["Wang M","Clark JI","Faust M","Chang E","Stella N","Patel V","Abbott S","Muchowski PJ"],"additional_accession":[]},"is_claimable":false,"name":"Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study.","description":"<h4>Study objectives</h4>Cannabidiol (CBD) is increasingly used as a health supplement, though few clinical studies have demonstrated benefits. The primary objective of this study was to evaluate the effects of an oral CBD-terpene formulation on sleep physiology in individuals with insomnia.<h4>Methods</h4>In this double-blind, placebo-controlled, randomized clinical trial, 125 individuals with insomnia received an oral administration of CBD (300 mg) and terpenes (1 mg each of linalool, myrcene, phytol, limonene, α-terpinene, α-terpineol, α-pinene, and β-caryophyllene) for ≥ 4 days/wk over 4 weeks using a crossover design. The study medication was devoid of Δ<sup>9</sup>-tetrahydrocannabinol. The primary outcome measure was the percentage of time participants spent in the combination of sl","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-13T04:52:27.635Z","creation":"2026-06-13T03:09:15.715Z"},"accession":"S-EPMC11701282","cross_references":{"pubmed":["39167421"],"doi":["10.5664/jcsm.11324"]}}